182 related articles for article (PubMed ID: 34631586)
1. Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines.
Lukoseviciute M; Maier H; Poulou-Sidiropoulou E; Rosendahl E; Holzhauser S; Dalianis T; Kostopoulou ON
Front Oncol; 2021; 11():748657. PubMed ID: 34631586
[TBL] [Abstract][Full Text] [Related]
2. Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell Lines.
Holzhauser S; Lukoseviciute M; Andonova T; Ursu RG; Dalianis T; Wickström M; Kostopoulou ON
Anticancer Res; 2020 Jan; 40(1):53-66. PubMed ID: 31892552
[TBL] [Abstract][Full Text] [Related]
3. Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines.
Holzhauser S; Lukoseviciute M; Papachristofi C; Vasilopoulou C; Herold N; Wickström M; Kostopoulou ON; Dalianis T
Int J Oncol; 2021 Feb; 58(2):211-225. PubMed ID: 33491755
[TBL] [Abstract][Full Text] [Related]
4. Targeted Therapy of HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy between CDK4/6, PI3K and Sometimes FGFR Inhibitors, but Rarely between PARP and WEE1 Inhibitors.
Kostopoulou ON; Zupancic M; Pont M; Papin E; Lukoseviciute M; Mikelarena BA; Holzhauser S; Dalianis T
Viruses; 2022 Jun; 14(7):. PubMed ID: 35891353
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines.
Lukoseviciute M; Holzhauser S; Pappa E; Mandal T; Dalianis T; Kostopoulou ON
Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37477144
[TBL] [Abstract][Full Text] [Related]
6. Targeted Therapy With PI3K and FGFR Inhibitors on Human Papillomavirus Positive and Negative Tonsillar and Base of Tongue Cancer Lines With and Without Corresponding Mutations.
Holzhauser S; Wild N; Zupancic M; Ursu RG; Bersani C; Näsman A; Kostopoulou ON; Dalianis T
Front Oncol; 2021; 11():640490. PubMed ID: 34046344
[TBL] [Abstract][Full Text] [Related]
7. Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy.
Chaturvedi NK; Kling MJ; Coulter DW; McGuire TR; Ray S; Kesherwani V; Joshi SS; Sharp JG
Oncotarget; 2018 Mar; 9(24):16619-16633. PubMed ID: 29682173
[TBL] [Abstract][Full Text] [Related]
8. Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer.
Sobhani N; Fassl A; Mondani G; Generali D; Otto T
Cells; 2021 Feb; 10(2):. PubMed ID: 33535617
[TBL] [Abstract][Full Text] [Related]
9. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2
Packer LM; Geng X; Bonazzi VF; Ju RJ; Mahon CE; Cummings MC; Stephenson SA; Pollock PM
Mol Cancer Ther; 2017 Apr; 16(4):637-648. PubMed ID: 28119489
[TBL] [Abstract][Full Text] [Related]
10. Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines.
Kostopoulou ON; Holzhauser S; Lange BKA; Ohmayer A; Andonova T; Bersani C; Wickström M; Dalianis T
Int J Oncol; 2019 Dec; 55(6):1372-1384. PubMed ID: 31638167
[TBL] [Abstract][Full Text] [Related]
11. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
[TBL] [Abstract][Full Text] [Related]
12. Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures.
Kähkönen TE; Toriseva M; Petruk N; Virta AR; Maher A; Eigéliené N; Kaivola J; Boström P; Koskivuo I; Nees M; Tuomela JM; Ivaska KK; Härkönen PL
Cell Oncol (Dordr); 2021 Feb; 44(1):205-218. PubMed ID: 33119860
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
Issa A; Gill JW; Heideman MR; Sahin O; Wiemann S; Dey JH; Hynes NE
Breast Cancer Res; 2013 Jan; 15(1):R8. PubMed ID: 23343422
[TBL] [Abstract][Full Text] [Related]
14. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
[TBL] [Abstract][Full Text] [Related]
15.
Holzhauser S; Kostopoulou ON; Ohmayer A; Lange BKA; Ramqvist T; Andonova T; Bersani C; Wickström M; Dalianis T
Oncol Lett; 2019 Dec; 18(6):6249-6260. PubMed ID: 31788102
[TBL] [Abstract][Full Text] [Related]
16. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins.
Koziczak M; Holbro T; Hynes NE
Oncogene; 2004 Apr; 23(20):3501-8. PubMed ID: 15116089
[TBL] [Abstract][Full Text] [Related]
17. Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.
Wojtalla A; Salm F; Christiansen DG; Cremona T; Cwiek P; Shalaby T; Gross N; Grotzer MA; Arcaro A
PLoS One; 2012; 7(10):e47109. PubMed ID: 23056595
[TBL] [Abstract][Full Text] [Related]
18. Combination of clotam and vincristine enhances anti-proliferative effect in medulloblastoma cells.
Patil S; Sankpal UT; Hurtado M; Bowman WP; Murray J; Borgmann K; Ghorpade A; Sutphin R; Eslin D; Basha R
Gene; 2019 Jul; 705():67-76. PubMed ID: 30991098
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between SHH and FGFR Signaling Pathways Controls Tissue Invasion in Medulloblastoma.
Neve A; Migliavacca J; Capdeville C; Schönholzer MT; Gries A; Ma M; Santhana Kumar K; Grotzer M; Baumgartner M
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31835472
[TBL] [Abstract][Full Text] [Related]
20. Estrogen and soy isoflavonoids decrease sensitivity of medulloblastoma and central nervous system primitive neuroectodermal tumor cells to chemotherapeutic cytotoxicity.
Belcher SM; Burton CC; Cookman CJ; Kirby M; Miranda GL; Saeed FO; Wray KE
BMC Pharmacol Toxicol; 2017 Sep; 18(1):63. PubMed ID: 28877739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
